Brain Scientific (OTCQB:BRSF), a Florida-based medical device technology company, today announces the immediate launch of the improved and updated NeuroCap™ device and the signing of a distribution partnership with D&D Medical, Inc. to sell the company’s neurological devices in Tennessee, Kentucky, Indiana and West Virginia.
D&D Medical, Inc. brings innovative medical technologies to market by training medical professionals in their use and distributing them where they are needed most.
“The NeuroCap makes EEG testing more convenient for patients and more efficient for clinicians,” said Don Sizemore, President of D&D Medical, Inc. “
NeuroCap meets the three criteria D&D Medical uses to select new technologies to represent: It offers a safer alternative for patients and clinicians, it is innovative and new, and it saves hospitals and patients money.
Brain Scientific’s newly improved NeuroCap recently went into production for the company and its distributors to build inventory and meet customer needs. Improvements to the NeuroCap include a proprietary gel with better conductivity, adhesive pads with improved performance, a more conductive, more precise ink formulation, and a base made from advanced blue PET material.
“Our improved NeuroCap is a more comfortable, user-friendly and efficient way to perform EEG studies,” said Hassan Kotob, Chairman and CEO of Brain Scientific. “With the now-available, single-use NeuroCap, clinicians can save prep time and see more patients, accelerating the timeline to results for critical EEG exams.”
Brain Scientific developed the NeuroCap to streamline EEG preparation, testing and diagnosis. NeuroCap features 22 pre-gelled electrodes, making it a suitable option for most clinical EEG testing, including routine EEGs commonly used in stroke and epilepsy patients. Fixed electrode placement conforms to the international 10-20 system.
The Brain Scientific NeuroCap is an FDA 510k cleared, pre-gelled, disposable EEG headset for clinical use. It allows any doctor to prepare a patient for an EEG scan in a fraction of the time it normally takes to apply individual electrodes. The NeuroCap can be used in almost any setting including rural hospitals, ambulances, private practices and sporting events, greatly expanding access to EEG testing. It is currently available in four sizes, including pediatric sizes.
About Brain Scientific
Brain Scientific (brainscientific.com) is a multi-patent medical technology company with FDA-cleared products. Brain Scientific is committed to developing next-generation solutions that drive the future of neurodiagnostic and medical OEM devices. Brain Scientific has two product lines covering Neurology and Precision Movement. NeuroCap™ and NeuroEEG™ are intelligent neurological diagnostic devices that simplify administration, reduce scan time and reduce costs. The Piezo Motion product line consists of highly efficient, compact, precision motors that will power the next generation of medical devices. To learn more about Brain Scientific’s corporate strategy, products or investor relations, please visit brainscientific.com.
All statements contained in this press release that are not historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) management’s plans and objectives for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of earnings (including earnings/losses), earnings (including earnings/losses) per share, capital expenditures, dividends, capital structure or other financial item; (iii) the future financial performance of the company; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in items (i), (ii), (iii) or (iv) above. Such forward-looking statements are not intended to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based on the Company’s current forecasts, plans, goals, beliefs, expectations, estimates and assumptions and these is subject to a number of risks and uncertainties and other influences, many of which are beyond the Company’s control. Actual results and the timing of certain events and circumstances could differ materially from those described in the forward-looking statements because of these risks and uncertainties. Factors that may affect or contribute to the inaccuracy of the forward-looking statements, or cause actual results to differ materially from those anticipated or desired, include, among others, the Company’s inability to obtain additional funding; the significant time and resources involved in developing products and the associated inadequate cash flows and resulting illiquidity; the Company’s inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the Company’s raw materials; and failure to implement the company’s business plans or strategies. Some of these and other factors are identified and described in more detail in the Company’s filings with the SEC. The company undertakes no obligation to update these forward-looking statements.
subject of research
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of the press releases published on EurekAlert! by contributing institutions or for the use of information about the EurekAlert system.